The authors critically discuss current knowledge regarding predictive biomarkers for checkpoint inhibitor-based immunotherapy, highlight the missing/unclear links and emphasise the importance of characterising each neoplasm and its microenvironment in order to better guide the course of treatment.
Pilard, C., Ancion, M., Delvenne, P., Jerusalem, G., Hubert, P., & Herfs, M. (2021). Cancer immunotherapy: it’s time to better predict patients’ response. British Journal of Cancer, 1–12. https://doi.org/10.1038/s41416-021-01413-xCite
The authors demonstrated that immune checkpoint molecules could be measured in cervicovaginal lavages. They identified CD40, CD27, and TIM-3 to specifically discriminate cervical cancer from other groups and CD40, CD28, and TLR2 to positively correlate to genital inflammation.
Łaniewski, P., Cui, H., Roe, D. J., Chase, D. M., & Herbst-Kralovetz, M. M. (2020). Vaginal microbiota, genital inflammation, and neoplasia impact immune checkpoint protein profiles in the cervicovaginal microenvironment. Npj Precision Oncology, 4(1), 1–9. https://doi.org/10.1038/s41698-020-0126-xCite